Serkan Çelik

The role of 68Ga-FAPi PET/CT in Staging and Restaging of Breast Cancer Subtypes with Limited 18F-FDG Uptake

Gamze Beydağı, Nalan Alan Selçuk, Kaan Akçay, Ayşegül Görmez et autres

Objectives: F-FDG PET/CT has low sensitivity. Methods: ) of primary tumors and metastases were recorded for both tracers and compared using paired t-tests. Results: in primary lesions and metastases (p<0.05). Conclusion: F-FDG-avid subtypes-supporting its potential role in clinical decision-making and treatment planning.

tr (code pays fourni par la source)

Systemic Anticancer Therapy Near the End of Life: Association of Treatment Escalation With Hospital-Centered Care in Metastatic Cancer: A Retrospective Cohort Study

Ezgi Çoban, Murat Sarı, Serkan Çelik, Bala Başak Öven

Background Systemic anticancer therapy (SAT) near the end of life is an indicator of potentially aggressive cancer care. Although patient-level prognostic factors have been studied, the role of treatment escalation within hospital-centered oncology models remains insufficiently understood. This study evaluated late-stage SAT …

tr (code pays fourni par la source)

The Role of [68Ga]Ga FAPi PET/CT in Staging and Restaging in Breast Cancer with Low FDG Uptake

Nalan Alan Selçuk, Gamze Beydağı, Kaan Akçay, Ayşegül Görmez et autres

tr (code pays fourni par la source)

Impact of 68Ga-FAPi PET/CT on Staging or Restaging Digestive System Tumors in Patients with Negative or Equivocal 18F-FDG PET/CT Findings

Nalan Alan Selçuk, Gamze Beydağı, Kaan Akçay, Emre E. Demirci et autres

Impact of 68 Ga-FAPi PET/CT on Staging or Restaging Digestive System Tumors in Patients with Negative or Equivocal 18 F-FDG PET/CT Findings Negatif veya Şüpheli 18 F-FDG PET/BT Bulguları olan Digestif Sistem Tümörlü Olguların Evrelenmesi ve Yeniden Evrelenmesinde 68 Ga-FAPi PET/BT'nin rolü

tr, us (code pays fourni par la source)

MANAGEMENT OF ONCOLOGIC DISEASES IN PATIENTS WITH MULTIMORBIDITY

Oğuzcan Kınıkoğlu, Serkan Çelik

Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study

Ebru Karcı, Ahmet Erkan Bilici, Buket Bayram, Melisa Celayir et autres

Background/Objectives: Following the results of the phase 3 KEYNOTE-522 trial, the U.S. Food and Drug Administration approved pembrolizumab, a humanized IgG4 kappa monoclonal antibody, in combination with neoadjuvant chemotherapy as a new standard of care for high-risk early-stage triple-negative breast cancer (TNBC). …

tr (code pays fourni par la source)

Investigating Combination Therapy: The Role of Lutetium-177 PSMA-617 Radioligand Therapy and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer

Oğuzcan Kınıkoğlu, Bala Başak Öven Ustaalıoğlu, Serkan Çelik, Nalan Alan Selçuk et autres

Background: The combination of Lutetium-177 (Lu-177) PSMA-617 radioligand therapy (RLT) with androgen receptor pathway inhibitors (ARPIs) has shown promise in metastatic castration-resistant prostate cancer (mCRPC). However, real-world data on the efficacy and safety of this combination are limited. This study aimed to …

tr (code pays fourni par la source)

“A chain of interlocking rings”: Preschool teachers’ experiences regarding home-school collaboration with a focus on children with special needs and their parents in inclusive education

Serkan Çelik, Gözde Tomris

tr (code pays fourni par la source)

Impact of the tumor proportion score (TPS) and the combined positive score (CPS) on the use of immunotherapy in patients with metastatic non-small cell lung cancer.

Duaa Kanan, Tarek Kanan, Serkan Çelik, Ezgi Hacıhasanoğlu et autres

e14611 Background: Expression of programmed cell death ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC) has often been measured by the Tumor Proportion Score (TPS) (1). Recently, the Combined Positive Score (CPS), which evaluates PD-L1 expression in tumor and inflammatory cells …

us, tr (code pays fourni par la source)

Integrated diagnosis of grade 3-4 gliomas using targeted next-generation sequencing and traditional diagnostic data, and its overall implications on patient management

Duaa Kanan, Şebnem Safi, Tarek Kanan, Serkan Çelik et autres

Adult gliomas vary significantly in terms of their genetics, epigenetics, phenotypes as well as clinical outcomes1. Optimal tumor classification that leads to more precise diagnoses, and which influences therapy selection is hence critically important. Targeted next-generation sequencing (NGS) is a highly reliable …

us, tr (code pays fourni par la source)

Revision of the Histopathological Examination Following 68Ga- DOTA-FAPI-04 PET/CT of a Breast Tumor Diagnosed as Invasive Ductal Carcinomatosis

Nalan Alan Selçuk, Kaan Akçay, Gamze Beydağı, Ömer Sönmez et autres

Neuroendocrine tumors (NETs) of the breast represent 1% of breast carcinomas. Histopathological misinterpretation of breast NET is common. We present the case of a female patient who had a breast mass diagnosed as invasive ductal carcinoma initially by histopathological examination. Fluorodeoxyglucose positron …

tr (code pays fourni par la source)

Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer

Nalan Alan Selçuk, Gamze Beydağı, Emre E. Demirci, Meltem Ocak et autres

For patients with advanced-stage metastatic castration-resistant prostate cancer (mCRPC) who do not respond to [177Lu]Lu-PSMA therapy, there are limited treatment options. Clinical results obtained with [225Ac]Ac-PSMA are promising. We retrospectively analyzed the outcomes of patients treated with [225Ac]Ac-PSMA between December 2018 and …

tr, us (code pays fourni par la source)